69728-92-3Relevant articles and documents
FURAN DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
-
Page/Page column 57, (2008/06/13)
A compound of formula: (I); or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl;
Synthesis and First Evaluation of New 18F-Labelled Sulfonylureas for the Determination of the Beta-Cell Status In Vivo
Schirrmacher, R.,Shiue, G.,Shiue, S. J.,Alavi, A.,Feilen, P. J.,Schneider, S.,Beyer, J.,Roesch, F.
, p. S418 - S420 (2007/10/03)
The syntheses and first in vitro evaluations for two fluoride bearing sulfonylurea derivatives are reported. Firstly, the tolbutamide derivative 1-[4-(2-[18F]fluoroethoxy)benzenesulfonyl]-3-butyl urea (2-[18F]fluoroethyltolbutamide) could be labeled efficiently with [18F]fluoride. Subsequently, the glibenclamid derivative N-(2-(4-(N-((cyclohexylamino)carbonyl)sulfonylamino)phenyl)ethyl) 2-(5-chloro-2-[18F]fluoroethoxy)phenyl formamide (2-[18F]fluoroethyl-glibenclamide) was labeled with [18F]fluoride in high yields. Its ability to induce insuline secretion from rat beta-cells in relation to the original glibenclamide was determined.